Company intelligence / Profile preview

Tai Tien Pharmaceuticals

Ownership: Private
Development stage: Other

Overview

Tai Tien Pharmaceuticals is a Taiwan-based pharmaceutical company focused on the commercialization of innovative drugs for lifestyle-related diseases and autoimmune disorders. It has launched several major products in Taiwan, including pitavastatin for hypercholesterolemia, canagliflozin for diabetic nephropathy/type 2 diabetes, fostamatinib for chronic ITP, and inebilizumab for neuromyelitis optica spectrum disorder. The company also markets established biologics such as infliximab and golimumab[4][5][6][7][10].

Therapeutic areas: CardiovascularNephrologyEndocrinologyImmunologyHematologyNeurology
Modalities: Small moleculeMonoclonal antibodyBiologic
Industry: Biotech

Partnerships

Kissei Pharmaceutical Co., Ltd. [sub-license agreement for fostamatinib/Tavalisse]Rigel Pharmaceuticals [original developer of fostamatinib]Johnson & Johnson Innovative Medicine [canagliflozin originator]

Beyond the preview

Go deeper on Tai Tien Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tai Tien Pharmaceuticals.

Explore the full profile